That's a great question.
Simply put, there are a number of organizations around the world that look to address this. The World Health Organization semi-annually produces a report that identifies the most dangerous drug-resistant organisms. It surveys around the world and does surveillance to understand those that are the greatest risk for humans. That's published semi-annually and prioritized into the highest concern, middle concern and lower concern but still of great concern. The CDC does something similar. Other jurisdictions do likewise.
With the surveillance in hospitals to understand the morbidity and mortality that these organisms cause, the lack of effective antibiotics is pretty clearly identified, so the pull incentives ought to be and have been designed to incentivize antibiotics that treat these most dangerous pathogens. It's important to keep that in mind. [Technical difficulty—Editor] that, and I believe the pilot would do exactly that.